Endolytix is a startup.
Endolytix is a startup.
Endolytix is developing lyticeuticals, a new class of drugs combining biological therapeutics with an advanced drug delivery platform to target non-tuberculous mycobacterial infections, aiming to improve treatment efficacy and reduce side effects compared to current therapies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.